Article Text

PDF
Secondary prevention for patients following a myocardial infarction: summary of NICE guidance
  1. J S Skinner1,
  2. A Cooper2,
  3. G S Feder3,
  4. on behalf of the Guideline Development Group
  1. 1Department of Cardiology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
  2. 2National Collaborating Centre for Primary Care, Royal College of General Practitioners, London, UK
  3. 3Centre for Health Sciences, Barts and the London Queen Mary’s School of Medicine and Dentistry, London, UK
  1. Correspondence to:
    Dr J S Skinner
    Consultant Community Cardiologist, Department of Cardiology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; Jane.Skinner{at}nuth.nhs.uk

Abstract

Mortality from coronary heart disease has been falling in the UK since the 1970s, but remains higher than in most other Western countries. Most patients receive some treatment for secondary prevention after myocardial infarction, but not all patients are offered the most effective secondary prevention package. The recently published NICE guideline for secondary prevention in patients after myocardial infarction, summarised in this article, makes clear recommendations for management of patients after myocardial infarction, based on best available evidence. The guidelines update the 2001 NICE guideline, and have expanded and emphasised the recommendations for physical activity, dietary and other lifestyle changes, and cardiac rehabilitation, and updated the recommendations for drug therapy.

Statistics from Altmetric.com

Footnotes

  • Funding: The National Collaborating Centre for Primary Care was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary.

  • Competing interests: All authors were members of the Guideline Development Group for the NICE guideline for secondary prevention after myocardial infarction. Dr Skinner was the clinical advisor, Dr Cooper the lead systematic reviewer and Professor Feder chaired the guideline development group. During the last 5 years Dr Skinner has received travel grants to attend educational meetings from Novartis, Pfizer and Sanofi Synthelabo/Bristol Myers Squibb Pharmaceuticals, with none during the last 2 years.

  • Declaration: A similar summary of this guideline has also been published in the BMJ2007;:–13 .

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles